Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Galactooligosaccharides are a **prebiotic oligosaccharide mixture** typically produced from lactose and used orally as a non-digestible carbohydrate to selectively stimulate beneficial gut microbes, especially *Bifidobacterium* spp. Rather than acting through a single receptor target, galactooligosaccharides function as a **microbiome-modulating substrate** that is fermented in the colon to short-chain fatty acids and other metabolites, with downstream effects on intestinal barrier integrity, stool characteristics, and mucosal immune tone. In the provided public sources, galactooligosaccharides were studied as a standalone prebiotic in obese adults, ulcerative colitis, overweight individuals, and in preclinical ALS models; they increased fecal bifidobacteria and improved markers of colonic permeability in obese adults, but did not show clear synergism when combined with probiotic strains in the cited synbiotic trial. This is a nutritional/prebiotic ingredient rather than a conventional pharmaceutical API, and commercial material in the cited human trial was supplied as Vivinal GOS by FrieslandCampina.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on galactooligosaccharides.